Bausch Health Companies Inc. 8-K

What Happened

• Bausch Health Companies Inc. filed an 8-K disclosing results of its Annual Meeting of Shareholders held May 19, 2026. Shareholders elected the full slate of directors (terms through the 2027 annual meeting), including new director Eiry W. Roberts, M.D., approved a non-binding advisory vote on executive compensation, and appointed PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm.
• Notable vote tallies from the filing include: Eiry W. Roberts, M.D. — For: 196,972,752; Withheld: 2,585,679; Broker Non-Votes: 79,859,606. Advisory vote on executive compensation — For: 189,432,400; Against: 9,588,417; Abstain: 537,614; Broker Non-Votes: 79,859,605. Appointment of PwC — For: 276,774,936; Withheld: 2,643,100.

Key Details

• Date: Annual Meeting held May 19, 2026.
• New director: Eiry W. Roberts, M.D., elected to serve until the 2027 Annual Meeting.
• Advisory compensation vote: 189.4M For vs. 9.6M Against (non-binding).
• Auditor appointment: PricewaterhouseCoopers LLP appointed with 276.8M For.

Why It Matters

• Board composition and governance: Election of the full slate (including a new director) determines who will oversee company strategy and oversight through 2027. Investors often watch director votes for signals about board independence and direction.
• Shareholder sentiment on pay: The non-binding “say-on-pay” passed with a strong majority (roughly 189M For), indicating shareholder support for disclosed executive compensation, though the vote is advisory and not legally binding.
• Auditor continuity: Reappointing PwC locks in the external auditor relationship through the next annual meeting, which affects audit continuity and reporting reliability.